Differential improvement in survival among patients with AIDS after the introduction of HAART

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 19, Issue 4, 2007, Pages 523-531

  Couzigou, C ^a,b   Semaille, C ^a   Strat, Y Le ^a   Pinget, R ^a   Pillonel, J ^a   Lot, F ^a   Cazein, F ^a   Vittecoq, D ^b   Desenclos, J C ^a   Vilde J L ^c   Yeni, P ^c   Sicard, D ^d,i   Kazatchkine, M ^e   Delcey, V ^f   Bricaire, F ^g   Herson, S ^g   Molina, J M ^h   Rozenbaum, W ^h   Sobel, A ^h   Cabane, J ⁱ   Girard, P M ⁱ   Pialoux, G ^j   more..

^a INSTITUT DE VEILLE SANITAIRE   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c BICHAT HOSPITAL   (France)

^d Hôpital Cochin ^*  (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f HÔPITAL LARIBOISIÈRE   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ HÔPITAL SAINT ANTOINE   (France)

^j HÔPITAL TENON   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS PATIENT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONFIDENCE INTERVAL; DEATH; DISEASE COURSE; DISEASE TRANSMISSION; FRANCE; HEALTH CENTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ABUSE; MONOTHERAPY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME; TUBERCULOSIS; TUMOR;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PARIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34247103057     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540120701235628     Document Type: Article

References (43)

1. Ancelle-Park, R., Klein, J.P., Stroobant, A., et al. (1993). Expanded European AIDS case definition. The Lancet, 341, 441.
2. Barron, Y., Cole, S.R., Greenblatt, R.M., et al. (2004). Effect of discontinuing antiretroviral therapy on survival of women initiated on highly active antiretroviral therapy. AIDS, 18, 1579-84.
3. Bates, I., Fenton, C., Gruber, J., et al. (2004). Vulnerability to malaria, tuberculosis, and HIV/AIDS infection and disease. Part 1: determinants operating at individual and household level. The Lancet Infectious Diseases, 4, 267-77.
4. Bernillon, P., Lievre, L., Pillonel, J., et al. (2000). Record-linkage between two anonymous databases for a capture-recapture estimation of underreporting of AIDS cases: France 1990-1993. The Clinical Epidemiology Group from Centres d'Information et de Soins de l'Immunodéficience Humaine. International Journal of Epidemiology, 29, 168-74.
5. Breen, R.A., Smith, C.J., Cropley, I., et al. (2005). Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy? AIDS, 19, 1201-06.
6. Celentano, D.D., Galai, N., Sethi, A.K., et al. (2001). Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS, 15, 1707-15.
7. Cole, S.R., Li, R., Anastos, K., et al. (2004). Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies. Statistics in medicine, 23, 3351-63.
8. Cole, S.R., Hernan, M.A., Margolick, J.B., et al. (2005). Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count. American Journal Epidemiology, 162, 471-78.
9. Conti, S., Masocco, M., Pezzotti, P., et al. (2000). Differential impact of combined antiretroviral therapy on the survival of Italian patients with specific AIDS-defining illnesses. Journal of Acquired Immune Deficiency Syndromes, 25, 451-58.
10. Detels, R., Munoz, A., McFarlane, G., et al. (1998). Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA, 280, 1497-50.
11. Del Amo, J., Petruckevitch, A., Phillips, A., et al. (1998). Disease progression and survival in HIV-1-infected Africans in London. AIDS, 12, 1203-09.
12. Dore, G.J., Li, Y., McDonald, A., et al. (2002). Impact of highly active antiretroviral therapy on individual AIDS- defining illness incidence and survival in Australia. Journal of Acquired Immune Deficiency Syndromes, 29, 388-95.
13. Dorrucci, M., Balducci, M., Pezzotti, P., et al. (1999). Temporal changes in the rate of progression to death among Italians with known date of HIV seroconversion: estimates of the population effect of treatment. Journal of Acquired Immune Deficiency Syndromes, 22, 65-70.
14. Fordyce, E.J., Singh, T.P., Nash, D., et al. (2002). Survival rates in NYC in the era of combination ART. Journal of Acquired Immune Deficiency Syndromes, 30, 111-18.
15. Friis-Moller, N., Weber, R., Reiss, P., et al. (2003). Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS, 17, 1179-93.
16. Glesby, M.J., & Hoover, D.R. (1996). Survivor treatment selection bias in observational studies: examples from the AIDS literature. Annals of Internal Medicine, 124, 999-1005.
17. Hammer, S.M., Squires, K.E., Hughes, M.D., et al. (1997). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. New England Journal of Medicine, 11, 725-33.
18. Heard, I., Tassie, J.M., Kazatchkine, M.D., et al. (2002). Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS, 16, 1799-802.
19. Hoffmann, C., Wolf, E., Fatkenheuer, G., et al. (2003). Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS, 17, 1521-29.
20. Holkova, B., Takeshita, K., Cheng, D.M., et al. (2001). Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. Journal of Clinical Oncology, 19, 3848-51.
21. Holtgrave, D.R., & Crosby, R.A. (2004). Social determinants of tuberculosis case rates in the United States. American Journal of Preventive Medicine, 26, 159-62.
22. INSERM-IFR69. Mise en oeuvre du décret n 98-37 autorisant l'accès aux données relatives au décès des personnes inscrites au Répertoire National d'Identification des Personnes Physiques (RNIPP) dans le cadre des recherches dans le domaine de la santé. (http://ifr69.vjf.inserm.fr/svcd.html). Accessed 28 November 2006.
23. Lot, F., Larsen, C., & Valin, N., et al. (2004). Parcours socio-médical des personnes originaires d'Afrique subsaharienne atteintes par le VIH, prises en charge dans les hôpitaux d'Ilede-France, 2002. Bulletin épidémiologique hebdomadaire, 5, 17-20. (http://www.invs.sante.fr/beh/2004/05/beh_05_2004.pdf). Accessed 28 November 2006.
24. Maggiolo, F., Ripamonti, D., Arici, C., et al. (2004). Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV clinical trials, 3, 371-8.
25. Marins, J.R., Jamal, L.F., Chen, S.Y., et al. (2003). Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS, 17, 1675-82.
26. Moatti, J.P., Carrieri, M.P., Spire, B., et al. (2000). Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. AIDS, 14, 151-55.
27. Mocroft, A., Katlama, C., Johnson, A.M., et al. (2000). AIDS across Europe, 1994-98: the EuroSIDA study. Lancet, 356, 291-96.
28. Mocroft, A., Ledergerber, B., Katlama, C., et al. (2003). Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet, 362, 22-29.
29. Palella, F.J., Jr., Delaney, K.M., Moorman, A.C., et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine, 338, 853-60.
30. Perez-Hoyos, S., del Amo, J., Muga, R., et al. (2003). Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS, 17, 353-59.
31. Porter, K., Babiker, A., Bhaskaran, K., et al. (2003). Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet, 362, 1267-74.
32. Rogers, P.A., Sinka, K.J., Molesworth, A.M., et al. (2000). Survival after diagnosis of AIDS among adults resident in the United Kingdom in the era of multiple therapies. Communicable Disease and Public Health, 3, 188-94.
33. Sackoff, J.E., Hanna, D.B., Pfeiffer, M.R., et al. (2006). Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Annals of Internal Medicine, 145, 397-406.
34. Schneider, M.F., Gange, S.J., Williams, C.M., et al. (2005). Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS, 19, 2009-18.
35. Schwarcz, S.K., Hsu, L.C., Vittinghoff, E., et al. (2000). Impact of protease inhibitors and other antiretroviral treatments on acquired immunodeficiency syndrome survival in San Francisco, California, 1987-1996. American Journal of Epidemiology, 152, 178-85.
36. Semaille, C., Pillonel, J., & Cazein, F., et al. (1997). Analyse de la survie des sujets atteints de Sida dans les principaux hôpitaux parisiens entre 1981 et 1993. Bulletin épidémiologique hebdomadaire, n 8. (http://www.invs.sante.fr/beh/1997/9708/index.html). Accessed 28 November 2006.
37. Staehelin, C., Rickenbach, M., Low, N., et al. (2004). Swiss HIV Cohort Study. Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival. AIDS Patient Care STDS, 4, 665-75.
38. Sterne, J.A., Hernan, M.A., Ledergerber, B., et al. (2005). Swiss HIV Cohort Study. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet, 366, 378-84.
39. Stone, V.E., Jordan, J., Tolson, J., et al. (2004). Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. Journal of Acquired Immune Deficiency Syndromes, 36, 808-16.
40. Tassie, J.M., Grabar, S., Lancar, R., et al. (2002). Clinical Epidemiology Group from the French Hospital Database on HIV. Time to AIDS from 1992 to 1999 in HIV-1-infected subjects with known date of infection. Journal of Acquired Immune Deficiency Syndromes, 30, 81-87.
41. Vlahov, D., Wang, C.L., Galai, N., et al. (2004). Mortality risk among new onset injection drug users. Addiction, 99, 946-54.
42. Vlahov, D., Galai, N., Safaeian, M., et al. (2005). Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. American Journal of Epidemiology, 161, 999-1012.
43. Wong, K.H., Chan, K.C., Lee, S.S., et al. (2004). Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy. Clinical Infectious Diseases, 39, 853-60.